INDV at a glance
Indivior Pharmaceuticals, Inc. (INDV, SEC CIK 1625297) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on October 6, 2026 and Form 4 insider filings as recently as August 27, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Indivior Pharmaceuticals, Inc. (INDV) reported revenue of $1.2 billion (up 4.3% from FY2024) and net income of $210.0 million. Diluted EPS was $1.64.
- As of June 30, 2026, 32 institutional investment managers tracked by SignalX reported holding Indivior Pharmaceuticals, Inc. (INDV) shares worth $2.6 billion in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Anderson Woodrow D on August 27, 2026 of 1,500 shares at $35.69 per share.
- In the last 90 days, INDV insiders reported 2 open-market purchases ($108K) and 1 open-market sale ($765K) on Form 4, a net sale of $657K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.2B
- +4.3% vs prior year
- Insiders · 90 days
- 2 buys · 1 sell
- Net −$657K
- 13F holders
- 32 funds
- $2.6B · +0 vs prior quarter
- Latest 8-K
- Sep 17, 2026
- Item 7.01 · Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: specialty pharmaceuticals focused on addiction treatment and opioid dependence therapies
- Emphasis on SUBLOCADE growth driving expected decline in U.S. revenue share from international markets this year
- Increasing regulatory focus on data privacy and security with rising investments and risks related to AI integration and cyber threats
- Foreign exchange risk heightened by 85% U.S. revenue concentration in 2025 and limited active currency hedging strategy
- Noteworthy: AI-related risks and vendor use of generative AI highlighted as emerging compliance and security challenges
Risk Factors
- FDA-required 2022 label change on SUBOXONE Film due to dental injury risk triggering ongoing product liability lawsuits
- Exposure to U.K. Financial Services and Markets Act 2000 claims over alleged misleading disclosure about SUBOXONE product-hopping scheme
- Single or dual sourcing for most raw materials and APIs risks supply interruption with average 36-month technology transfer delay to new suppliers
- 2023 entry of a competitor’s extended-release injectable buprenorphine challenges SUBLOCADE’s market share in once-monthly OUD treatment
- Leveraged balance sheet and term loan covenants constraining financial flexibility amid potential revenue declines
Management Discussion & Analysis
- Revenue increased by $87M in 2025 vs $28M in 2024 from prior year performance obligations adjustments
- No profitability or operating margin figures disclosed in the text
- No forward-looking guidance or risk outlook mentioned in the provided section
AI summary of the INDV 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Pending Supernus merger subject to stockholder and regulatory approvals, with completion timing uncertain
- Merger failure risk includes substantial termination fee exposure and transaction costs
- Contractual restrictions during merger could limit acquisitions, indebtedness, dividends, capital expenditures, and claim settlements
- Fixed 1.5401 exchange ratio exposes Indivior shareholders to stock-price volatility before closing
- Integration risk could prevent realization of anticipated merger synergies, growth, profitability, and earnings accretion
AI summary of the INDV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Exhibit 99.1 furnished under Regulation FD, signaling accompanying investor-relevant disclosure
- Information not treated as filed under Exchange Act Section 18
Item EX-99.1: Item EX-99.1
- $8.13-per-share special dividend declared for Indivior shareholders of record October 30, 2026
- Payment contingent on Supernus merger closing, currently expected around November 2, 2026
Item 8.01: Other Events
- $8.13-per-share special cash dividend declared, contingent on Indivior’s acquisition of Supernus closing
- Record date October 30, 2026; payment anticipated around November 6, 2026, assuming November 2 closing
Item 1.02: Termination of a Material Definitive Agreement
- RB’s SUBOXONE® and SUBUTEX® tablet manufacturing agreement terminates early on January 15, 2027
- New supplier identified, with enforceable obligations beginning after manufacturing-process validation
AI summaries of INDV 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for INDV
Don't miss the next INDV filing
- Alerts as it files. A push when INDV files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut INDV, by share count.
- Ask anything. An AI agent that reads every INDV filing and answers with sources.
INDV alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Anderson Woodrow D | Buy | Aug 27, 2026 | 1,500 | $35.69 |
| Anderson Woodrow D | Buy | Aug 5, 2026 | 1,500 | $36.28 |
| Heidbreder Christian | Sell | Jul 10, 2026 | 18,586 | $41.14 |
| Ciaffoni Joseph | M | Jun 22, 2026 | 1,266,903 | - |
| Ciaffoni Joseph | M | Jun 22, 2026 | 1,266,903 | - |
| Ciaffoni Joseph | F | Jun 22, 2026 | 612,549 | $38.32 |
| Heidbreder Christian | Sell | Jun 11, 2026 | 18,586 | $38.06 |
| Preblick Ryan | Sell | Jun 8, 2026 | 36,000 | $37.70 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.2B | $1.2B |
| Gross Profit | - | $957.0M | $994.0M |
| Operating Income | - | $32.0M | $262.0M |
| Net Income | - | $2.0M | $210.0M |
| Gross Margin | - | 80.6% | 80.2% |
| Op. Margin | - | 2.7% | 21.1% |
| Net Margin | - | 0.2% | 16.9% |
| Balance Sheet | |||
| Total Assets | - | $1.3B | $1.2B |
| Equity | - | -$348.0M | -$98.0M |
| ROE | - | -0.6% | -214.3% |
| Per Share | |||
| EPS | $-0.94 | $0.02 | $1.64 |
| Cash Flow | |||
| Operating CF | - | $36.0M | -$27.0M |
| CapEx | $8.0M | $29.0M | $66.0M |
Source: XBRL data in Indivior Pharmaceuticals, Inc. (INDV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate INDV share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 32 | $2.59B |
| Q1 2026 | 32 | $1.91B |
- Franklin Resources+3.20M (+2872%)
- T. Rowe Price Group+816.2K (+587%)
- Citigroup+588.5K (+1080%)
- Dimensional Fund Advisors+564.5K (+42%)
- Invesco Ltd+281.2K (+18%)
- Millennium Management−2.50M (-54%)
- Goldman Sachs Group−1.71M (-71%)
- Citadel Advisors LLC−906.2K (-25%)
- Vanguard Portfolio Management LLC−319.5K (-4%)
- JPMorgan Chase & Co−270.3K (-50%)
- M&T Bank+6.4K
- Marex Group plc−13.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 64 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
INDV filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 6, 2026 | - | - | - |
| 8-K | Sep 17, 2026 | - | Analysis | - |
| 8-K | Sep 15, 2026 | - | Analysis | - |
| 4 | Aug 27, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 4 | Jul 13, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 10, 2026 | - | - | |
| 8-K | May 15, 2026 | - | Analysis | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 8-K | May 4, 2026 | - | Analysis | - |
| 8-K | Apr 30, 2026 | - | Analysis | - |
| 10-Q | Apr 30, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Apr 28, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
INDV SEC filings: frequently asked questions
Are INDV insiders buying or selling?
In the last 90 days, Indivior Pharmaceuticals, Inc. (INDV) officers, directors and 10% owners reported 2 open-market purchases worth $107,955 by 1 insider and 1 open-market sale worth $764,628 by 1 insider on Form 4, a net sale of $656,673. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold INDV stock?
As of June 30, 2026, the largest Indivior Pharmaceuticals, Inc. (INDV) holders among the 13F filers tracked by SignalX were BlackRock ($767.6 million), Vanguard Portfolio Management LLC ($310.7 million), Vanguard Capital Management LLC ($225.5 million), State Street Corp ($204.8 million), Morgan Stanley ($139.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was INDV's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Indivior Pharmaceuticals, Inc. (INDV) reported revenue of $1.2 billion (up 4.3% from FY2024) and net income of $210.0 million. Diluted EPS was $1.64. The figures come from the XBRL data in the 10-K.
What are the main risks in INDV's latest 10-K?
In the 10-K filed February 26, 2026, Indivior Pharmaceuticals, Inc. (INDV) flagged: FDA-required 2022 label change on SUBOXONE Film due to dental injury risk triggering ongoing product liability lawsuits. Exposure to U.K. Financial Services and Markets Act 2000 claims over alleged misleading disclosure about SUBOXONE product-hopping scheme. (AI summary of the Risk Factors section.)
What did INDV report in its latest 8-K?
Indivior Pharmaceuticals, Inc. (INDV) filed an 8-K on September 17, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). Exhibit 99.1 furnished under Regulation FD, signaling accompanying investor-relevant disclosure.
What are the latest INDV SEC filings?
Indivior Pharmaceuticals, Inc. (INDV) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on October 6, 2026 and a Form 4 insider filing on August 27, 2026.
What is INDV's SEC CIK number?
Indivior Pharmaceuticals, Inc. (INDV)'s SEC Central Index Key (CIK) is 1625297. EDGAR lists every INDV filing under that number.
Ask anything about INDV
The research agent reads INDV's filings, financials, insider trades and 13F holders, then answers with sources.